124 related articles for article (PubMed ID: 23159638)
1. Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells.
Hemdan NY
Immunol Lett; 2013 Jan; 149(1-2):123-33. PubMed ID: 23159638
[TBL] [Abstract][Full Text] [Related]
2. [The role of stromal mast cells in the modification of CD4+CD25+Foxp³ regulatory T cells, Th17 lymphocytes and cytotoxic lymphocytes Tc1 in the development and progression of tumor].
Starska K; Brzezińska-Błaszczyk E
Postepy Hig Med Dosw (Online); 2010 Aug; 64():408-16. PubMed ID: 20966498
[TBL] [Abstract][Full Text] [Related]
3. Th17 Cell Plasticity and Functions in Cancer Immunity.
Guéry L; Hugues S
Biomed Res Int; 2015; 2015():314620. PubMed ID: 26583099
[TBL] [Abstract][Full Text] [Related]
4. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer.
Iida T; Iwahashi M; Katsuda M; Ishida K; Nakamori M; Nakamura M; Naka T; Ojima T; Ueda K; Hayata K; Nakamura Y; Yamaue H
Oncol Rep; 2011 May; 25(5):1271-7. PubMed ID: 21369705
[TBL] [Abstract][Full Text] [Related]
6. The paradox of Th17 cell functions in tumor immunity.
Asadzadeh Z; Mohammadi H; Safarzadeh E; Hemmatzadeh M; Mahdian-Shakib A; Jadidi-Niaragh F; Azizi G; Baradaran B
Cell Immunol; 2017 Dec; 322():15-25. PubMed ID: 29103586
[TBL] [Abstract][Full Text] [Related]
7. Key molecules in the differentiation and commitment program of T helper 17 (Th17) cells up-to-date.
Hemdan NY; Birkenmeier G; Wichmann G
Immunol Lett; 2012 Dec; 148(2):97-109. PubMed ID: 23036716
[TBL] [Abstract][Full Text] [Related]
8. Green tea EGCG, T cells, and T cell-mediated autoimmune diseases.
Wu D; Wang J; Pae M; Meydani SN
Mol Aspects Med; 2012 Feb; 33(1):107-18. PubMed ID: 22020144
[TBL] [Abstract][Full Text] [Related]
9. Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?
Martin F; Apetoh L; Ghiringhelli F
Trends Mol Med; 2012 Dec; 18(12):742-9. PubMed ID: 23083809
[TBL] [Abstract][Full Text] [Related]
10. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.
Miyahara Y; Odunsi K; Chen W; Peng G; Matsuzaki J; Wang RF
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15505-10. PubMed ID: 18832156
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis.
Eljaafari A; Tartelin ML; Aissaoui H; Chevrel G; Osta B; Lavocat F; Miossec P
Arthritis Rheum; 2012 Jul; 64(7):2147-57. PubMed ID: 22275154
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
[TBL] [Abstract][Full Text] [Related]
13. IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis.
Yamashita T; Iwakura T; Matsui K; Kawaguchi H; Obana M; Hayama A; Maeda M; Izumi Y; Komuro I; Ohsugi Y; Fujimoto M; Naka T; Kishimoto T; Nakayama H; Fujio Y
Cardiovasc Res; 2011 Sep; 91(4):640-8. PubMed ID: 21622681
[TBL] [Abstract][Full Text] [Related]
14. Unlike αβ T cells, γδ T cells, LTi cells and NKT cells do not require IRF4 for the production of IL-17A and IL-22.
Raifer H; Mahiny AJ; Bollig N; Petermann F; Hellhund A; Kellner K; Guralnik A; Reinhard K; Bothur E; Huber M; Bauer S; Löhning M; Kiss EA; Ganal SC; Diefenbach A; Korn T; Lohoff M
Eur J Immunol; 2012 Dec; 42(12):3189-201. PubMed ID: 22961652
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
[TBL] [Abstract][Full Text] [Related]
16. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
17. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
Yoshida H; Kimura A; Fukaya T; Sekiya T; Morita R; Shichita T; Inoue H; Yoshimura A
Biochem Biophys Res Commun; 2012 Feb; 418(2):234-40. PubMed ID: 22252297
[TBL] [Abstract][Full Text] [Related]
18. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.
Nishihara M; Ogura H; Ueda N; Tsuruoka M; Kitabayashi C; Tsuji F; Aono H; Ishihara K; Huseby E; Betz UA; Murakami M; Hirano T
Int Immunol; 2007 Jun; 19(6):695-702. PubMed ID: 17493959
[TBL] [Abstract][Full Text] [Related]
19. Targeting the development and effector functions of TH17 cells.
Ghilardi N; Ouyang W
Semin Immunol; 2007 Dec; 19(6):383-93. PubMed ID: 18083530
[TBL] [Abstract][Full Text] [Related]
20. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.
Eriksen KW; Søndergaard H; Woetmann A; Krejsgaard T; Skak K; Geisler C; Wasik MA; Odum N
Mol Immunol; 2009 Feb; 46(5):812-20. PubMed ID: 18947877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
